Benzinga.com

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst

Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed 16.9% to $585.7 million, with international sales up 33.5%. See the seasonal trading ...
Seeking Alpha

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the ...
Seeking Alpha

Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience

New 100 mg/dL Target Glucose setting offers more customization and tighter glucose management. Enhanced algorithm helps users remain in Automated Mode to improve the user experience. Most requested ...
Nasdaq

PODD Stock Benefits From the Launch of Omnipod 5 in Canada

Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) system commercially available in Canada for people with type 1 diabetes (ages two years and above). Omnipod 5 is ...
Nasdaq

Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...